Moleculin Biotech, Inc. Profile Avatar - Palmy Investing

Moleculin Biotech, Inc.

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment …

Biotechnology
US, Houston [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Moleculin Biotech, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Moleculin Biotech, Inc. can't present revenue by segment

Get PRO Today

With PRO you can bypass the blur for the segment revenues of Moleculin Biotech, Inc..

If you want to see a demo, head over to the financial segments of AAPL

End of MBRX's Analysis
CIK: 1659617 CUSIP: 60855D200 ISIN: US60855D2009 LEI: - UEI: -
Secondary Listings
MBRX has no secondary listings inside our databases.